A study of tumour infiltrating lymphocytes and neutrophil to lymphocyte ratio in papillary carcinoma thyroid
DOI:
https://doi.org/10.18203/2320-6012.ijrms20230872Keywords:
Papillary carcinoma thyroid, Tumour infiltrating lymphocytes, Neutrophil to lymphocyte ratioAbstract
Background: Papillary thyroid carcinoma accounts for 70-80% of all diagnosed thyroid carcinomas. Immune response including systemic inflammation is thought to be essential for suppression of carcinogenesis. This study aims to correlate the tumour infiltrating lymphocytes (TIL) and neutrophil to lymphocyte ratio (NLR) in various demographic data and histomorphological features of papillary carcinoma thyroid.
Methods: A total of 60 cases of papillary carcinoma were taken from a period between January 2018 and July 2021. TIL was analyzed as diffuse or focal at the area of highest concentration and was graded subjectively as: absent (no lymphocytes), mild (1-10%), moderate (>10-50%) and dense (>50%). NLR was calculated as the neutrophil count divided by the lymphocyte count, based on the preoperative complete blood cell counts.
Results: The cases belonged to age group varying from 20 to 75 years with female preponderance (88.3%). In this study, there was significant correlation between TIL and tumour stage with a p value of 0.001. Lower the tumour stage, higher was the concentration of TIL. A cut of value of 2.17 was taken for NLR. Cases with diffuse, moderate to dense peritumoural lymphocytes had lower NLR and were statistically significant. High NLR was also seen in higher TNM stage. On the other hand, there were no association with gender, age, tumour size, histological subtype and focality with NLR.
Conclusions: As an index of inflammation, tumour infiltrating lymphocytes and NLR can be considered. We found increased TIL in lower tumour stage and increased NLR values in higher tumour stages.
Metrics
References
Villagelin DG, Santos RB, Romaldini JH. Is diffuse and peritumoural lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis? J Endocrinol Invest. 2011;34(11):e403-8.
Nimmagadda A, Mohan VK, Manthri R, Kalawat TC. Unusual metastases in papillary microcarcinoma of thyroid. Indian J Nucl Med. 2019;34(1):32.
Manatakis DK, Tseleni-Balafouta S, Balalis D, Soulou VN, Korkolis DP, Sakorafas GH, Plataniotis G, Gontikakis E. Association of baseline neutrophil-to-lymphocyte ratio with clinicopathological characteristics of papillary thyroid carcinoma. Int J Endocrinol. 2017;5:21-9.
Weber F. Lymphocytes and thyroid cancer: more to it than meets the eye?. Endocr Relat. Cancer. 2014;21(3):C1-5.
Kuo CY, Liu TP, Yang PS, Cheng SP. Characteristics of lymphocyte-infiltrating papillary thyroid cancer. J Cancer Res Pract 2017;4(3):95-9.
Ari A, Gunver F. Comparison of neutrophil–lymphocyte ratio and platelet–lymphocyte ratio in patients with thyroiditis and papillary tumours. J Int Med Res. 2019;47(5):2077- 83.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74.
Okayasu I. The Relationship of Lymphocytic Thyroiditis to the Development of Thyroid Carcinoma. Endocr Pathol. 1997;8:225–30.
Kebebew E, Treseler PA, Ituarte PH, Clark OH. Coexisting chronic lymphocytic thyroiditis and papillary thyroid cancer revisited. World J Surg. 2001;25:632–7.
Huang BY, Hseuh C, Chao TC, Lin KJ, Lin JD. Well-differentiated thyroid carcinoma with concomitant Hashimoto’s thyroiditis present with less aggressive clinical stage and low recurrence. Endocrine Pathol. 2011;22(3):144-9.
Bagnasco M, Venuti D, Paolieri F, Torre G, Ferrini S, Silvano GW. Phenotypic and functional analysis at the clonal level of infiltrating T lymphocytes in papillary carcinoma of the thyroid: prevalence of cytolytic T cells with natural killer-like or lymphokine-activated killer activity. J Clin Endocrinol Metab. 1989;69(4):832-6.
Kimura HI, Yamashita SH, Namba HI, Tominaga T, Tsuruta MA, Yokoyama NA, et al. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab 1992;75(2):596-602.
Reines BP. Bystanders or Bad Seeds? Many Autoimmune-target Cells May Be Transforming to Cancer and Signalling “Danger” to the Immune System. Autoimmunity. 2001;33(2):121-34.
Grivennikov SI, Karin M. Inflammation and oncogenesis: a vicious connection. Curr Opin Genet Dev 2010;20(1):65-71.
Muranski P, Restifo NP. Essentials of Th17 cell commitment and plasticity. Am J Hematol 2013;121(13):2402-14.
Stassi G, Todaro M, Zerilli M, Ricci-Vitiani L, Di Liberto D, Patti M, et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 2003;63(20):6784-90.
Russell JP, Engiles JB, Rothstein JL. Proinflammatory mediators and genetic background in oncogene mediated tumour progression. J Immunol 2004;172(7):4059-67.
Feng J, Wang Y, Shan G, Gao L. Clinical and prognostic value of neutrophil-lymphocyte ratio for patients with thyroid cancer: A meta-analysis. Medicine. 2020;99(20):423-8
Cheong TY, Hong SD, Jung KW, So YK. The diagnostic predictive value of neutrophilto-lymphocyte ratio in thyroid cancer adjusted for tumour size. Plos one. 2021;16(5):22-9.
Templeton AJ, McNamara MG, Šeruga B. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumours: a systematic review and meta-analysis. J Natl cancer Inst. 2014;106(6):1-11.
Liu CL, Lee J, Liu T, Chang Y, Hsu YC, Cheng SP. Blood neutrophil-to-lymphocyte ratio correlates with tumour size in patients with differentiated thyroid cancer. J Surg Oncol. 2013;107(5):493-7.
Seretis C, Gourgiotis S, Gemenetzis G, Seretis F, Lagoudianakis E, Dimitrakopoulos G. The significance of neutrophil/lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study. Am J Surg. 2013;205(6):691-6.
Downloads
Published
How to Cite
Issue
Section
